NovArtis

Our global portfolio of innovative patented medicines includes more than 50 key marketed products, many of which are among the leaders in their therapeutic areas. We invest in the development of new technologies that improve patient adherence and help predict individual response to treatment. Our goal is to optimize patient outcomes by delivering targeted treatments.

By beginning to genetically identify patients who will respond positively to particular therapies, we are starting to tackle two of the greatest challenges in developing drugs: identifying a disease area with a critical, unmet need and assigning studies to test a clinical hypothesis.

Teams across Novartis work together to develop customized therapies for patients.